trial summary · NCT07629583
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cevostamab in Patients With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Trial record from the TrialBase DB dataset, status RECRUITING, condition Lupus Erythematosus, Systemic, sponsored by Genentech, Inc.. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN).
Source record: https://clinicaltrials.gov/study/NCT07629583
Facts
| registry id | NCT07629583 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | Lupus Erythematosus, Systemic |
| sponsor | Genentech, Inc. |
| sponsor class | INDUSTRY |
| enrollment | 46 |
| start date | 2026-10-31 |
| primary completion | 2030-03-29 |
| completion | 2030-03-29 |
| results posted | not reported |
Conditions
- Lupus Erythematosus, Systemic
Interventions
- Cevostamab
- Tocilizumab
Countries
- France
- Spain
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.